MRK241206P84000
- 0.01
- 0.000.00%
Merck & Co Newsroom
Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
EMD Serono Appoints Miguel Fernández Alcalde to Lead North American Healthcare Business
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Dow Down 150 Points On Losses For Shares Of Caterpillar, 3M
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
Today's Analyst Rating | Tesla Price Target Raised to $400 by Morgan Stanley, Oracle Price Target Raised to $194 by Citi
Express News | B of A Securities Reinstates Buy on Merck & Co, Announces $121 Price Target
Merck & Co Analyst Ratings
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Merck Reports Positive Phase 2 Data for Zilovertamab Vedotin
Merck's Keytruda Combined With Chemotherapy and Lynparza Regimen Meets Phase 3 Primary Endpoint
Express News | Merck & Co Inc - Safety Profiles of Keytruda and Lynparza Consistent With Previous Studies
Express News | Merck & Co Inc - Study Did Not Reach Secondary Endpoint of Overall Survival
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Express News | Merck Announces Phase 3 Keylynk-001 Trial Met Primary Endpoint of Progression-Free Survival (Pfs) in Patients With Advanced Epithelial Ovarian Cancer